These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6828101)

  • 1. Plasma carbamylated protein in renal failure.
    Oimomi M; Ishikawa K; Kawasaki T; Kubota S; Yoshimura Y; Baba S
    N Engl J Med; 1983 Mar; 308(11):655-6. PubMed ID: 6828101
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbamylated plasma protein in renal failure.
    Oimomi M; Nishimoto S; Matsumoto S; Hatanaka H; Ishikawa K; Kawasaki T; Yoshimura Y; Baba S
    Nihon Jinzo Gakkai Shi; 1986 Mar; 28(3):269-71. PubMed ID: 3723861
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in plasma binding of ortho-iodobenzoate and ortho-iodohippuran in patients with kidney and liver diseases].
    Láznícek M; Kvĕtina J; Mazák J; Krch V; Kvĕtinová M; Srámek B
    Cesk Farm; 1987 Apr; 36(3):97-102. PubMed ID: 3594587
    [No Abstract]   [Full Text] [Related]  

  • 4. Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
    Wang Z; Nicholls SJ; Rodriguez ER; Kummu O; Hörkkö S; Barnard J; Reynolds WF; Topol EJ; DiDonato JA; Hazen SL
    Nat Med; 2007 Oct; 13(10):1176-84. PubMed ID: 17828273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of the binding between uric acid and plasma proteins (author's transl)].
    Sforza GR; Marcolongo R; Della Fazia L; Masciangelo F; Morozzi G; Lo Cosmo C
    Quad Sclavo Diagn; 1980 Dec; 15(4):1075-89. PubMed ID: 7454962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State analysis of endogenous cyanate ion in human plasma.
    Koshiishi I; Imanari T
    J Pharmacobiodyn; 1990 Apr; 13(4):254-8. PubMed ID: 2117063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alkylisocyanide complexes of various vertebrate and invertebrate hemoglobins].
    Ruckpaul K; Jung W; Buttgereit K; Jung F
    Acta Biol Med Ger; 1970; 24(1):33-45. PubMed ID: 5534767
    [No Abstract]   [Full Text] [Related]  

  • 8. Determination of carbamylated plasma protein and its clinical application to renal failure.
    Oimomi M; Matsumoto S; Hatanaka H; Ishikawa K; Kubota S; Yoshimura Y; Baba S
    Nephron; 1985; 40(4):405-6. PubMed ID: 4022208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protein binding of sulphachlorpiridacine (author's transl)].
    Mariño EL; Tabernero JM; Macías JG; Domínguez-Gil A; de Castro S
    Arch Farmacol Toxicol; 1979 Aug; 5(2):107-16. PubMed ID: 533316
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH).
    Perna AF; Ingrosso D; Molino D; Galletti P; Montini G; Zacchello G; Bellantuono R; Caringella A; Fede C; Chimenz R; De Santo NG
    J Nephrol; 2003; 16(4):516-21. PubMed ID: 14696753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protein & lipid pictures in renal patients].
    DIAZ-RUBIO M; JANER DEL VALLE C
    Rev Clin Esp; 1958 Aug; 70(4):209-18. PubMed ID: 13614838
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.
    Plum A; Müller LK; Jansen JA
    Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):139-43. PubMed ID: 10893694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins.
    Kraus LM; Kraus AP
    Wien Klin Wochenschr; 1998 Aug; 110(15):521-30. PubMed ID: 9782570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma binding of pancuronium: effects of age, sex, and disease.
    Wood M; Stone WJ; Wood AJ
    Anesth Analg; 1983 Jan; 62(1):29-32. PubMed ID: 6849508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of renal failure in rats on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins.
    Liu JH; Malone RS; Stallings H; Smith PC
    J Pharmacol Exp Ther; 1996 Jul; 278(1):277-83. PubMed ID: 8764361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Change in the pharmacokinetics of drug substances in kidney diseases].
    Kudrin AN; Davydova ON; Androsova SO
    Klin Med (Mosk); 1980 May; 58(5):13-6. PubMed ID: 6991802
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in plasma proteins and drug distribution in kidney and liver diseases].
    Manojlović Z; Kopitar Z; Lenardic A; Plavsić F
    Lijec Vjesn; 1993; 115(11-12):366-9. PubMed ID: 8177001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in blood silicon concentration in patients with renal failure.
    Mauras Y; Riberi P; Cartier F; Allain P
    Biomedicine; 1980 Nov; 33(7):228-30. PubMed ID: 7225501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophoretic study of proteins in various kidney diseases; paper method].
    PHILIPPI F; MORALES J; LAZCANO F; BARAONA E
    Rev Med Chil; 1957 Nov; 85(11):656-61. PubMed ID: 13528114
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of paper electrophoresis in various kidney diseases].
    BOGDANIKOWA B
    Pol Tyg Lek (Wars); 1958 Jun; 13(22):832-5. PubMed ID: 13578751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.